Epitope-based vaccination against pneumonic tularemia.

[1]  D. Metzger,et al.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. , 2008, Vaccine.

[2]  K. Elkins,et al.  The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. , 2008, The Journal of infectious diseases.

[3]  Nita H. Salzman,et al.  A Francisella tularensis Schu S4 Purine Auxotroph Is Highly Attenuated in Mice but Offers Limited Protection against Homologous Intranasal Challenge , 2008, PloS one.

[4]  Y. Li,et al.  Utilization of Fc Receptors as a Mucosal Vaccine Strategy against an Intracellular Bacterium, Francisella tularensis1 , 2008, The Journal of Immunology.

[5]  J. Sedgwick,et al.  Differential Requirements by CD4+ and CD8+ T Cells for Soluble and Membrane TNF in Control of Francisella tularensis Live Vaccine Strain Intramacrophage Growth , 2007, The Journal of Immunology.

[6]  J. Alroy,et al.  Identification of Immunologic and Pathologic Parameters of Death versus Survival in Respiratory Tularemia , 2007, Infection and Immunity.

[7]  D. Metzger,et al.  Prophylactic and Therapeutic Use of Antibodies for Protection against Respiratory Infection with Francisella tularensis1 , 2007, The Journal of Immunology.

[8]  K. Elkins,et al.  Innate and Adaptive Immunity to Francisella , 2007, Annals of the New York Academy of Sciences.

[9]  D. Metzger,et al.  Mucosal Immunopathogenesis of Francisella tularensis , 2007, Annals of the New York Academy of Sciences.

[10]  P. Oyston,et al.  Vaccines Against Francisella Tularensis , 2007, Annals of the New York Academy of Sciences.

[11]  Julie A McMurry,et al.  Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. , 2007, Vaccine.

[12]  D. Metzger,et al.  Inactivated Francisella tularensis Live Vaccine Strain Protects against Respiratory Tularemia by Intranasal Vaccination in an Immunoglobulin A-Dependent Fashion , 2007, Infection and Immunity.

[13]  B. Sahay,et al.  Toll-Like Receptor 2 Is Required for Control of Pulmonary Infection with Francisella tularensis , 2006, Infection and Immunity.

[14]  N. Van Rooijen,et al.  Kupffer cells abrogate cholestatic liver injury in mice. , 2006, Gastroenterology.

[15]  Terry H Wu,et al.  Intranasal Vaccination Induces Protective Immunity against Intranasal Infection with Virulent Francisella tularensis Biovar A , 2005, Infection and Immunity.

[16]  D. Metzger,et al.  Intranasal Interleukin-12 Treatment for Protection against Respiratory Infection with the Francisella tularensis Live Vaccine Strain , 2005, Infection and Immunity.

[17]  Wangxue Chen,et al.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. , 2005, Vaccine.

[18]  Anders Sjöstedt,et al.  The complete genome sequence of Francisella tularensis, the causative agent of tularemia , 2005, Nature Genetics.

[19]  D. Heymann.  Control of Communicable Diseases Manual , 2004 .

[20]  A. Sjöstedt,et al.  Tularaemia: bioterrorism defence renews interest in Francisella tularensis , 2004, Nature Reviews Microbiology.

[21]  M. Horwitz,et al.  Virulent and Avirulent Strains of Francisella tularensis Prevent Acidification and Maturation of Their Phagosomes and Escape into the Cytoplasm in Human Macrophages , 2004, Infection and Immunity.

[22]  M. Gerstein,et al.  Comparing protein abundance and mRNA expression levels on a genomic scale , 2003, Genome Biology.

[23]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[24]  M. Perry,et al.  Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. , 2002, Vaccine.

[25]  K. Ishii,et al.  Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides1 , 2001, The Journal of Immunology.

[26]  J. Siddiqui,et al.  Eotaxin Represents the Principal Eosinophil Chemoattractant in a Novel Murine Asthma Model Induced by House Dust Containing Cockroach Allergens1 , 2001, The Journal of Immunology.

[27]  R. Titball,et al.  Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. , 2001, Vaccine.

[28]  Philip K. Russell,et al.  Tularemia as a biological weapon: medical and public health management. , 2001, JAMA.

[29]  K. Ishii,et al.  CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression. , 2000, Cellular immunology.

[30]  A. Sjöstedt,et al.  Evaluation of PCR-Based Methods for Discrimination ofFrancisella Species and Subspecies and Development of a Specific PCR That Distinguishes the Two Major Subspecies of Francisella tularensis , 2000, Journal of Clinical Microbiology.

[31]  A. Sjöstedt,et al.  The requirement of tumour necrosis factor-α and interferon-γ for the expression of protective immunity to secondary murine tularaemia depends on the size of the challenge inoculum , 1996 .

[32]  R. Titball,et al.  Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence. , 1996, FEMS immunology and medical microbiology.

[33]  R. B. Narayanan,et al.  Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth , 1995, Infection and immunity.

[34]  A. Sjöstedt,et al.  CD4+ and CD8+ T-cell-dependent and -independent host defense mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice , 1994, Infection and immunity.

[35]  A. Woods,et al.  Human major histocompatibility complex class II-restricted T cell responses in transgenic mice , 1994, The Journal of experimental medicine.

[36]  A. Tärnvik.  Nature of protective immunity to Francisella tularensis. , 1989, Reviews of infectious diseases.

[37]  H. Wilson,et al.  Tularemia vaccine study. II. Respiratory challenge. , 1961, Archives of internal medicine.

[38]  H. Wilson,et al.  Tularemia vaccine study. I. Intracutaneous challenge. , 1961, Archives of internal medicine.

[39]  A. Sjöstedt,et al.  Rapid local expression of interleukin-12, tumor necrosis factor alpha, and gamma interferon after cutaneous Francisella tularensis infection in tularemia-immune mice. , 1999, Infection and immunity.

[40]  B. A. Cunha,et al.  Tularemia pneumonia. , 1997, Seminars in respiratory infections.

[41]  R. Titball,et al.  Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. , 1995, Vaccine.

[42]  M. Spence,et al.  Increased encapsulation and virulence of Francisella tularensis live vaccine strain (LVS) by subculturing on synthetic medium. , 1994, Vaccine.

[43]  M. Evans.  TULAREMIA: A 30 YEAR EXPERIENCE WITH 88 CASES , 1986 .

[44]  F. Detrick.  Immunization against Tularemia: Analysis of the Effectiveness of Live Francisella tularensis Vaccine in Prevention of Laboratory-Acquired Tularemia , 1977 .

[45]  T. Guthe,et al.  Syphilis. Review of the recent literature, 1959-1960. , 1961, Archives of internal medicine.